Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. Researchers now describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs. Their studies, conducted in cell and animal models of melanoma, demonstrate that the combined therapy could destroy a subset of drug-resistant cells within a tumor.